OxThera AB						
Name of study	**Objective**	**Major Inclusion criteria**	**Major exclusion criteria**	**Major time points**	**Centers participating in Europe**	**More information available at**
OC5-DB-02 (ePHex study)	To evaluate the efficacy of Oxabact® following 52 weeks treatment in patients with maintained kidney function but below the lower limit of the normal range (eGFR < 90 ml/min/1.73 m^2) and a total plasma oxalate concentration ≥ 10 µmol/L at baseline.	1. Signed informed consent 2. Diagnosis of PH. 3. eGFR < 90 ml/min/1.73 m^2. 4. Total plasma oxalate concentration ≥10 µmol/L 5. ≥ 2 years of age 6. stable vitamin B6 for at least 3 months prior to screening and must not change the dose during the study.	1. Inability to swallow size 4 capsules. 2. Previous transplantation (solid organ or bone marrow). 3. Patients requiring dialysis or at immediate risk for kidney failure 4. Secondary hyperoxaluria 5. Use of antibiotics to which O. formigenes is sensitive	Baseline, week 24, week 52	UK: • Nottingham Children's Hospital • Royal Free Hospital -UCL Germany: Kindernierenzentrum Bonn Belgium: Centre Hospitalier Universitaire de Liège USA: Vanderbilt University Hospital Spain: Hospital Universitari Vall d' Hebron	www.oxthera.com www.clinicaltrials.gov

					Tunisia: • Hedi Chaker University Hospital, Sfax • Hôpital Charles-Nicolle, Tunis • Hôpital Sahloul, Sousse	
OC5-OL-02 (ePHex-OLE study)	To evaluate the efficacy of Oxabact® following two years continued treatment in subjects who have completed the Oxabact® OC5-DB-02 (ePHex) study.	1. Signed informed consent 2. Participation in and completion of study ePHex.	Same as above	Baseline, week 52, week 104	Same as above	www.oxthera.com www.clinicaltrials.gov